News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Sepracor, Inc. Announces Fourth Quarter And Full Year 2006 Results
January 31, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sepracor Inc. (Nasdaq: SEPR) today announced its consolidated financial results for the fourth quarter and full year 2006.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Earnings
Sanofi targets late-phase and commercial M&A to offset looming Dupixent decline
October 30, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
‘We need to do better,’ Alnylam CEO admits, as uncertainty looms over transthyretin franchise
October 30, 2026
·
3 min read
·
Annalee Armstrong
Venture capital
New biotech Setara forms with $90M to take on Jazz’s bonus rare disease programs
October 30, 2026
·
1 min read
·
Annalee Armstrong
Drug Development
Dren Bio lands $350M to push rare blood cancer therapy toward market
October 29, 2026
·
2 min read
·
Gabrielle Masson
